Skip to Content
Merck
  • Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis.

Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis.

Oncotarget (2015-01-13)
Poomy Pandey, Satyanarayana Rachagani, Srustidhar Das, Parthasarathy Seshacharyulu, Yuri Sheinin, Naava Naslavsky, Zenggang Pan, Brittney L Smith, Haley L Peters, Prakash Radhakrishnan, Nicole R McKenna, Sai Srinivas Panapakkam Giridharan, Dhanya Haridas, Sukhwinder Kaur, Michael A Hollingsworth, Richard G MacDonald, Jane L Meza, Steve Caplan, Surinder K Batra, Joyce C Solheim
ABSTRACT

Amyloid precursor-like protein 2 (APLP2) is aberrantly expressed in pancreatic cancer. Here we showed that APLP2 is increased in pancreatic cancer metastases, particularly in metastatic lesions found in the diaphragm and intestine. Examination of matched human primary tumor-liver metastasis pairs showed that 38.1% of the patients had positive APLP2 expression in both the primary tumor and the corresponding liver metastasis. Stable knock-down of APLP2 expression (with inducible shRNA) in pancreatic cancer cells reduced the ability of these cells to migrate and invade. Loss of APLP2 decreased cortical actin and increased intracellular actin filaments in pancreatic cancer cells. Down-regulation of APLP2 decreased the weight and metastasis of orthotopically transplanted pancreatic tumors in nude mice.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human APLP2
Sigma-Aldrich
D-Luciferin, synthetic, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
D-Luciferin, synthetic
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Aplp2
Sigma-Aldrich
3,3′-Diaminobenzidine, 97%
Sigma-Aldrich
3,3′-Diaminobenzidine, 97% (HPLC)